Incidence of acute kidney injury in COVID-19 infection: a systematic review and meta-analysis

Abstract

Coronavirus disease 2019 (COVID-19), primarily affecting respiratory systems, has become pandemic and spread worldwide. Acute kidney injury (AKI) has been reported as a severe complication of COVID-19 with a higher risk of mortality [1], but the incidence of AKI among those infected with COVID-19 is currently only based on reports from small case series and retrospective studies [2, 3]. Therefore, in this work, we aim to perform a systematic review and meta-analysis of published articles to quantify the incidence of AKI in COVID-19 patients. We performed a systematic search via PUBMED and EMBASE using the keywords “COVID-19” and “acute kidney injury” to identify relevant observational studies, such as case series and cohort studies published between 2019 and May 11, 2020. We also manually examined the reference lists of included studies and reviewed the AKI reports in epidemiological features and clinical courses of COVID-19 patients in high-profile general medicine journals (e.g., BMJ, JAMA, Lancet, and NEJM). Two independent reviewers (YTC and SCS) assessed articles, including title, abstract, and full text to determine whether studies were eligible for inclusion. In cases of divergences, results were discussed with a third reviewer (YCC). All statistical analyses were performed using MedCalc for Windows, version 15.0 (MedCalc Software, Ostend, Belgium). The incidence of AKI is expressed as proportion and 95% confidence interval (CI) using the random effects model and presented as a forest plot. We used the Cochran Q test to detect heterogeneity among studies, with a p value < 0.10 indicating significant heterogeneity. We calculated I 2 statistic to measure the proportion of total variation in study estimates attributed to heterogeneity. Of 65 articles screened, we excluded 45: 7 studies were duplicates, 8 studies were irrelevant, 9 studies failed to report the number of patients in the study cohort, and 21 studies did not report AKI data. Our final analysis included 20 articles comprising 6945 patients from China, Italy, the UK, and the USA. Demographic data for the included articles are summarized in Table 1. Notably, most of the studies (80%) were reported from China. We found the incidence of AKI was 8.9% (95% CI 4.6–14.5) in COVID-19 patients, but there was evidence of statistical heterogeneity among the studies with I 2 = 97.8% and p < 0.001 (Fig. 1). Table 1 Study characteristics Author and year City/country Male (%) Age (median)* Settings Patients with kidney transplantation (%) Mechanical ventilation (%) RRT (%) ARDS (%) Overall mortality (%) Alberici 2020 [4] Brescia/Italy 80 59 Hospitalization 100 10 5 55 25 Arentz 2020 [5] Washington/USA 52 70 ICU NR 71 NR 95 52 Banerjee 2020 [6] London/UK 57 54 Hospitalization 100 29 43 29 14 Chen 2020 [7] Wuhan/China 68 56 Hospitalization NR 4 9 17 11 Chen 2020 [8] Wuhan/China 62 62 Hospitalization NR 6 1 72 41 Cheng 2020 [9] Wuhan/China 52 63 Hospitalization NR 14 NR NR 16 Deng 2020 [10] Wuhan/China 55 54 Hospitalization NR 9 NR 48 48 Guan 2020 [11] Wuhan/China 58 47 Hospitalization NR 2 1 3 1 Guo 2020 [12] Wuhan/China 49 59 Hospitalization NR 24 NR 25 23 Huang 2020 [13] Wuhan/China 73 49 Hospitalization NR 10 7 29 15 Lei 2020 [14] Wuhan/China 41 55 Hospitalization NR 15 3 32 21 Richardson 2020 [15] New York/USA 60 63 Hospitalization NR 12 3 NR 21 Shi 2020 [16] Wuhan/China 49 64 Hospitalization NR 8 1 23 14 Wang 2020 [17] Wuhan/China 58 54 Hospitalization NR NR NR 10 6 Wang 2020 [18] Wuhan/China 54 56 Hospitalization NR 12 1 20 4 Wang 2020 [19] Wuhan/China 53 51 Hospitalization NR 19 NR 26 18 Yang 2020 [20] Wuhan/China 67 60 ICU NR 42 17 67 62 Zhang 2020 [21] Wuhan/China 49 55 Hospitalization NR 12 2 22 5 Zhang 2020 [22] Zhejiang/China 51 45 Hospitalization NR 1 0 2 NR Zhou 2020 [23] Wuhan/China 62 56 Hospitalization NR 17 5 31 28 *In studies not reporting the median, age would be represented by the mean ARDS acute respiratory distress syndrome, ICU intensive care unit, NR not reported, RRT renal replacement therapy Fig. 1 Forest plot of pooled incidence of AKI in COVID-19 patients from included studies Previous studies reported the incidence of AKI largely from small case series or cohorts of COVID-19 patients, but our findings indicated that nearly 9 out of 100 developed AKI among a total of 6945 COVID-19 patients. This was close to the incidence rate of AKI in patients with community-acquired pneumonia [24]. Several mechanisms are possible for AKI in COVID-19 patients, including multi-organ dysfunction syndrome, SARS-CoV-2 direct kidney infection [25], AKI following acute respiratory distress syndrome (ARDS), infection-related generalized mitochondrial failure, and cytokine storm syndrome. Early recognition and treatment of AKI may limit associated complications such as long-term chronic kidney disease or end-stage kidney disease [26]. This study has several limitations. First, since the majority of included studies came from China and the USA, the generalizability of our findings into other countries may be limited. Second, clinical heterogeneity between studies should be noted, whereby detailed information on patient characteristics was lacking in the published articles. For example, two studies included patients post kidney transplantation, and the reported incidences of AKI were higher than in other studies which lacked information on how many patients had had kidney transplantation. With the disease burden of COVID-19 still increasing every day, we hope our synthesis can raise clinical awareness, early recognition, and intervention for AKI in patients hospitalized with COVID-19 for first-line healthcare providers.